Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of CKD-375 and D390 in Healthy Adults
NCT04221360Phase 1Unknown
- Sponsor
- Chong Kun Dang Holdings
- Start
- Jan 2020
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of empagliflozin and liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve to the Last Measurable Concentration. Status: unknown.
02
Drugs
empagliflozinliquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04221360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04221360.